Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Alkermes plc (NASDAQ: ALKS).

Full DD Report for ALKS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALKS)

FDA OKs first non-opioid treatment for opioid withdrawal
The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read ...
Source: SeekingAlpha
Date: May, 16 2018 16:44
Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference
DUBLIN , May 14, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 2:00 p.m. ET ( 7:00 p.m. BST ) from New York . The presentation may be acce...
Source: PR Newswire
Date: May, 14 2018 16:01
Alkermes (ALKS) Webinar On ALKS 3831 Drug - Slideshow
The following slide deck was published by Alkermes plc in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 11 2018 13:34
Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference
DUBLIN , May 10, 2018 /PRNewswire/ --  Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:20 a.m. PT ( 2:20 p.m. ET / 7:20 p.m. BST ) from ...
Source: PR Newswire
Date: May, 10 2018 16:01
Lundbeck Gets An Unexpected Boon From The FDA
Things really do seem a little different at the FDA these days. The FDA's commissioner, Scott Gottlieb, has talked openly of wanting the agency to take a different approach to its interactions with the biopharma industry, speeding up processes, removing certain roadblocks, and generally shifti...
Source: SeekingAlpha
Date: May, 04 2018 14:58
Key events next week - healthcare
Noteworthy events during the week of May 6 - 12 for healthcare investors. More news on: Lipocine Inc., Neurovive Pharmaceutical AB, Akcea Therapeutics, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 04 2018 09:51
Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders Research
DUBLIN , May 4, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced a new competitive awards program, the ALKERMES Pathways Research Awards SM Program , which is designed to support the next generation of researchers who are working on the front lines to advance...
Source: PR Newswire
Date: May, 04 2018 07:00
Alkermes to Host Webcast and Conference Call to Discuss ALKS 3831 Development Program
DUBLIN , May 3, 2018 /PRNewswire/ --   Alkermes plc (Nasdaq: ALKS) today announced that it will host an educational webinar on Thursday, May 10, 2018 to discuss ALKS 3831, an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of schiz...
Source: PR Newswire
Date: May, 03 2018 16:00
Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank 43rd Annual Health Care Conference
DUBLIN , May 2, 2018 /PRNewswire/ --  Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Deutsche Bank 43 rd Annual Health Care Conference on Wednesday, May 9, 2018 at 10:00 a.m. ET ( 3:00 p.m. BST ) from Boston . The presen...
Source: PR Newswire
Date: May, 02 2018 16:00
Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual Meeting
DUBLIN , April 30, 2018 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced the presentation of six posters highlighting data from the company's schizophrenia and depression portfolios at the 2018 American Psychiatric Association (APA) Annual Meeting in New York , May 5...
Source: PR Newswire
Date: April, 30 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1747.5646.0147.6745.44822,854
2017-02-0355.4354.9555.4353.895630,091
2017-02-0254.5655.2355.4853.69805,474
2017-02-0154.4554.7054.9652.791,268,003
2017-01-3151.9854.1154.3051.081,329,144

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1732,48560,01554.1281Short
2018-08-1697,083118,95281.6153Short
2018-08-1552,43667,90677.2185Short
2018-08-1435,53491,51238.8299Short
2018-08-1333,19780,95441.0072Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALKS.


About Alkermes plc (NASDAQ: ALKS)

Logo for Alkermes plc (NASDAQ: ALKS)

Not available

 

Contact Information

 

 

Current Management

  • Richard F. Pops / CEO
  • Robert A. Breyer / President, COO
  • Michael J. Landine / CFO

Current Share Structure

  • Market Cap: $7,292,980,464 - 05/14/2018
  • Issue and Outstanding: 155,037,850 - 04/20/2018

 


Recent Filings from (NASDAQ: ALKS)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 10 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 19 2018

 

 


Daily Technical Chart for (NASDAQ: ALKS)

Daily Technical Chart for (NASDAQ: ALKS)


Stay tuned for daily updates and more on (NASDAQ: ALKS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ALKS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALKS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ALKS and does not buy, sell, or trade any shares of ALKS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/